This clinical trial is focused on studying the effects of a medication called Atorvastatin in people who have Chronic Obstructive Pulmonary Disease (COPD). COPD is a long-term lung disease that makes it hard to breathe. The study aims to see if Atorvastatin can help reduce the number of times patients experience worsening symptoms, known as exacerbations. Atorvastatin is a type of medication commonly used to lower cholesterol, but this study is exploring its potential benefits for people with COPD. Participants in the study will either receive Atorvastatin or a placebo, which looks like the medication but does not contain the active ingredient.
The purpose of the study is to compare how well Atorvastatin works against a placebo in reducing COPD exacerbations. Participants will take the medication or placebo for a period of time, and researchers will monitor their health to see how often exacerbations occur and how long they last. The study will also look at other health aspects, such as lung function, quality of life, and certain markers in the blood that indicate inflammation. These markers include things like the number of white blood cells and levels of proteins that can show how the body is responding to the disease.
Throughout the study, participants will have regular check-ups to assess their lung function and overall health. This includes measuring how much air they can breathe out in one second, known as forced expiratory volume (FEV1), and how far they can walk in six minutes. The study will also track any hospital visits related to COPD. By the end of the study, researchers hope to better understand whether Atorvastatin can be a helpful treatment for people with COPD, potentially improving their quality of life and reducing the frequency of exacerbations.
Poland 
